Radiotherapy is the standard therapy for nasopharyngeal carcinoma (NPC); however, radioresistance can hinder successful treatment. Here we report that microRNA (miR)-24 acts as a tumor suppressor and radiosensitizer in NPC cells and xenografts by targeting Jab1/CSN5. Although accumulating evidence has shown that Jab1/CSN5 functions as an oncoprotein in human cancers, its regulation through miRs has not been described. In this study, we found that Jab1/CSN5 functioned in a manner opposite to that of miR-24 in NPC tumorigenesis and radioresistance. We demonstrated that miR-24 inhibits Jab1/CSN5 translation via direct binding to its 3′ untranslated region (3′UTR) and 5′UTR, leading to tumor growth inhibition, and sensitizes NPC tumors to radiation in vivo. Furthermore, silencing Jab1/CSN5 phenocopied the function of miR-24 in NPC cells after ionizing radiation treatment, resulting in increased apoptosis. Finally, we analyzed 50 paired samples of primary and matched recurrent NPC tissues from 25 NPC patients and subjected them to high-throughput genomic quantitative nuclease protection assay for quantifying simultaneously miR and mRNA levels. Our results showed that miR-24 levels were significantly decreased in recurrent NPC and that levels of Jab1/CSN5, as its target, were higher than those in primary NPC. Together, our findings indicate that miR-24 inhibits NPC tumor growth and increases NPC radiosensitivity by directly regulating Jab1/CSN5 and that both miR-24 and Jab1/CSN5 can serve as prognostic markers for NPC recurrence; this, in turn, may provide a promising therapeutic strategy for reversing NPC radioresistance.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) is a head and neck malignancy with local invasion and early distant metastasis. It is endemic to Southern China, Southeast Asia, Northern Africa and Alaska. Epstein-Barr virus infection, genetic susceptibility and endemic environmental factors are believed to be the main etiological factors of NPC. [1] [2] [3] Owing to the distinct anatomical location (pharyngeal recess) and relative high radiosensitivity of NPC, radiotherapy is the mainstay treatment for primary NPC presenting at early stages. In recent decades, concurrent chemotherapy and radiotherapy have been recommended as a standard treatment for NPC patients at late stages. 4 Nevertheless, local failure or regional failure presenting as persistent or recurrent tumor still occurs and radioresistance remains the main cause of NPC treatment failure. 5 Therefore, its urgent to elucidate the mechanism of NPC radioresistance to identify biomarkers for clinical therapy optimization and to develop novel effective treatment strategies.
MicroRNAs (miRs) are a class of small non-coding RNAs (of about 22 nucleotides in length) that regulate levels of multiple proteins, primarily by binding to the 3′ untranslated region (UTR) of their target mRNAs and suppressing protein translation. [6] [7] [8] [9] Mature miRs act as trans-acting factors capable of degrading or suppressing the expression of mRNA targets, and around 60% of genes may be regulated by miRs. 10 miRs have emerged as important epigenetic regulators of gene-encoding proteins, and aberrant miR expression has been found in many cancers, including NPC. 11 However, the role of miR expression in radioresistance remains to be characterized.
MiR-24 is clustered with miR-23 and miR-27 at two genomic loci: (1) the miR-24-1 gene cluster (chromosome 9q22.32), encoding miR-23b, -27b and -24-1; and (2) the miR-24-2 gene cluster (chromosome 19p13.13), encoding miR-23a, -27a and -24-2. 4 Studies have shown that miR-24 can inhibit cancer cell proliferation 12 and promote cancer cell apoptosis, 13 indicating its role as a tumor suppressor. However, miR-24 has been found to have different roles in several cancers. For example, it inhibits HeLa cell proliferation 14 and represses cell death in gastric cancers, 15 showing its role as an onco-miR. It has been documented that miRs can be valuable in manipulating the tumor radiation response in the clinic to enhance susceptibility to radiation. 16 Therefore, in this study we investigated the potential role of miR-24 as a novel therapeutic target to reverse NPC radioresistance. Jab1/CSN5 (c-Jun activation domain-binding protein-1, Jab1 hereafter) was originally identified as a c-Jun co-activator by our group 17 and subsequently discovered by other groups as the fifth member and an integral component of the constitutive photomorphogenic-9 signalosome complex (CSN5). 18 As one of the eight core subunits (CSN1-CSN8 in order of descending size), it not only harbors the catalytic center of CSN isopeptidase activity but also stably exists independently of the CSN complex in vivo. 18 It participates in multiple cellular processes, both as part of the CSN-associated complex and as free forms independently of the CSN complex. 19 Accumulating evidence has shown that Jab1 functions as an oncoprotein in human cancers. Jab1 is overexpressed in multiple human cancers, including hepatocellular carcinoma 20 and NPC, 21 and its overexpression is positively correlated with poor survival rate in various human malignancies. 22 Our group recently found that Jab1 contributes to NPC tumorigenesis and resistance to radiotherapy by promoting NPC cell growth, dysregulating NPC cell cycle progression and inhibiting radiation-induced apoptosis. [21] [22] [23] Previous investigation by our group showed that Jab1 deletion sensitized both primary embryonic fibroblasts and osteosarcoma cells to γ-radiation-induced apoptosis and increased spontaneous DNA damage and homologous recombination defects. 24 These findings indicate the critical role of Jab1 in cancer development and radiotherapy failure.
Ionizing radiation (IR) damages cells by producing intermediate ions and free radicals, leading to increased DNA damage including DNA double-strand breaks and genomic instability. 16 Increased DNA damage response has been reported to be one of the mechanisms of radioresistance. 25 Jab1 is critically involved in DNA damage response and is linked to the maintenance of genome integrity. [24] [25] [26] Loss of Jab1 leads to spontaneous DNA breaks that are associated with increased expression of the histone γ-H2AX, initiating the recruitment of DNA damage response proteins. 24 In NPC cells, Jab1 deletion could reduce the capacity of NPC cells to repair DNA lesions by reducing Rad51 (a key protein in the homologous recombination repair pathway) expression. 27 These findings suggest that Jab1 has a crucial role in radioresistance via increasing DNA repair ability and decreasing IRinduced cell apoptosis, indicating that blocking Jab1 might be a feasible and appealing approach to sensitize NPC cells to radiotherapy.
To date, no study has explained why Jab1 is overexpressed or regulated in NPC. In this current study, we first demonstrated that miR-24 functioned as an NPC cell growth inhibitor and a radiosensitizer for NPC radiotherapy both in vitro and in vivo, which is the opposite of the effect of Jab1 in NPC. Therefore, we hypothesized that miR-24 might be the molecule upstream of Jab1 leading to its overexpression during radiotherapy and therefore to NPC radioresistance. To test our hypothesis, we investigated the correlation between miR-24 and Jab1 in vitro and in vivo and used the luciferase assay to validate the binding sites of miR-24 to Jab1. The inverse correlation between miR-24 and Jab1 was then confirmed by the high-throughput genomic quantitative nuclease-protection assay (qNPA) in NPC primary and recurrent patient samples. In addition, miR-24 downregulation or Jab1 upregulation in NPC recurrent tissues compared with primary paired tissues is closely associated with a shorter interval from initial treatment to NPC recurrence, indicating potential roles of miR-24 and Jab1 as prognostic markers for NPC recurrence and in novel therapeutic strategies for treating NPC patients. However, whether miR-24 contributes to the progression of NPC or radioresistance and the underlying mechanism remains poorly understood. In the present study, we showed that miR-24 inhibits NPC and increases NPC radiosensitivity by directly targeting Jab1, suggesting a tumor-suppressor role for miR24 in NPC. Our finding suggested that the restoration of miR-24 levels in tumors provide a promising therapeutic strategy for NPC treatment.
RESULTS
Low expression of miR-24 promotes NPC cell growth and resists NPC cells to IR Our previous study has shown that miR-24 had an important role in NPC. 28 To further identify the precise role of miR-24 in NPC, we overexpressed miR-24 by transfecting NPC cells (CNE-2, CNE-2R, CNE-1, HONE-1 and C666.1) with miR-24 mimics (Supplementary Figure S1A ). NPC cell growth was inhibited (450%) (Supplementary Figure S1B ) and cell apoptosis was induced (about sixfold) (Supplementary Figure S1C ) in a dose-dependent manner by ectopic miR-24 expression. Furthermore, the colonyforming ability of NPC cells was suppressed by miR-24 overexpression and was further inhibited when miR-24-overexpressing cells were treated with IR ( Figure 1a , P o 0.001). Conversely, miR-24 inhibition with miR-24 inhibitors increased the colonyforming ability of NPC cells and significantly reduced NPC cell response to irradiation (Supplementary Figure S1D, Figure 1b ). Taken together, our results showed that miR-24 functions as a tumor-suppressive miR in NPC and could sensitize NPC cells to irradiation in vitro.
MiR-24 inhibits NPC xenografts and sensitizes NPC tumors to radiation in vivo
The in vitro data above showed the critical role of miR-24 in NPC cells. To further confirm the function of miR-24 in NPC, we established NPC cells stably overexpressing miR-24 by infecting CNE-2R with a lentivirus (LV) mir-LV-24-1 or mir-LV-control. Colonies were selected to confirm the miR-24 expression level by quantitative real-time PCR (qRT-PCR) analysis. Our results showed about a 10-fold increase in miR-24 levels in colony #2 and a 6-fold increase in colony #1 compared with the cells expressing mir-LV-ctrl ( Figure 2a ).
We then transplanted the colony #2 cells stably overexpressing miR-24 into nude mice and treated the mice with IR when tumors were palpable ( Figure 2b ). As shown in Figure 2c , tumor weight was significantly lower (twofold) compared with tumors from cells infected with mir-LV-control. Consistently, the xenograft mouse model also showed the suppressive effects of miR-24 on tumor growth (around 60% and 80% inhibition at days 19 and 22, respectively). When mice were treated with IR, tumor weight was significantly lower (3.8-fold) in the miR-24-overexpressing group than in the control group without IR. Moreover, tumor growth was reduced significantly (around threefold at day 16) when compared with cells infected with a control LV (Figure 2d , top panel). As expected, when combined with IR treatment, there was a significant difference (around sixfold at day 16) between the miR-24-overexpressing group and controls (Figure 2d , bottom panel). Our findings suggest that miR-24 functions as a tumor suppressor in NPC tumorigenicity and may improve the efficacy of NPC radiotherapy.
Jab1 is a direct target of miR-24
In vitro and in vivo studies demonstrated that ectopic restoration of miR-24 could significantly inhibit NPC cell growth and growth of NPC xenografts and could enhance the sensitivity of both NPC cells and xenografts to IR. How it functions in NPC, however, remains to be elucidated. Our previous findings indicated that miR-24 targets Jab1/CSN5 in nasopharyngeal carcinoma S Wang et al Jab1 is a key regulator of several signaling pathways. It acts as a putative oncogene in NPC and increases NPC radioresistance. [21] [22] [23] Interestingly, Jab1 has the opposite function of miR-24 in NPC. We therefore hypothesized that Jab1 might be a target of miR-24. To investigate this hypothesis, we used a computational target prediction algorithm, RNAhybrid, to identify the binding motifs of miR-24 to the 3′UTR or 5′UTR of Jab1. 29, 30 Minimum free energies (MFEs) are determined from the optimization of duplexes between a miR and a putative target sequence. In our case, as shown in Figure 3a , both 3′UTR (153 bp; MFE: − 18.1 kcal/mol) and 5′UTR (331 bp; MFE: − 24.8 kcal/mol) of Jab1 harbored a targeting sequence by miR-24 with rational and applicable MFEs.
Next, to validate that Jab1 is a direct target of miR-24, we used three miR luciferase constructs containing the 3′UTR or 5′UTR of Jab1, pMIR-luc-Jab1 3′UTR and pMIR-luc-Jab1 5′UTR, located at 1462-1479 nt and 231-255 nt, respectively, and also test the Jab1 5′UTR inserted upstream of the luciferase-coding region, pMIR-luc-Jab1 5′UTR Upstream (Figure 3b ). Treatment of co-transfected CNE-2 cells with miR-24 mimics markedly reduced luciferase activity in cells with miR reporter pMIR-luc-Jab1 3′UTR (approximately 60%, Figure 3c ) or pMIR-luc-Jab1 5′UTR (approximately 50%, Figure 3c ), indicating that both the 3′UTR and 5′UTR are functional binding sites of miR-24. Repeating the experiments with the Jab1 5′UTR inserted upstream of the luciferase-coding region gave similar results (approximately 50% inhibition, Figure 3c ). To further confirm the specific nature of the miR-24-mRNA interaction, the sequences within the pMIR-luc-Jab1 3′UTR (AGCU deletion) or pMIR-luc-Jab1 5′UTR (GUUC deletion) binding sites were mutated, resulting in the total loss of miR-24-mediated repression of luciferase activity (Figure 3d ). These findings support the notion that miR-24 directly targets both binding sites within the 3′UTR and 5′UTR of Jab1 mRNA to exert an inhibitory effect on Jab1 expression.
The functional significance of miR-24 was further evaluated under conditions of miR-24 overexpression and attenuation in multiple NPC cell lines. Forced expression of miR-24 mimics led to a robust increase in mature miR-24 levels (Supplementary Figure S1A ). Accordingly, western blotting analysis confirmed that Jab1 expression decreased dramatically (up to 90%) at both the mRNA ( Figure 3e ) and protein levels (Figure 3f , Supplementary  Figures S2A and B ) in a dose-and time-dependent manner, indicating that miR-24-mediated reduction of Jab1 is mediated by mRNA degradation. Conversely, there was a significant increase in Jab1 protein levels ( Figure 3g ) following miR-24 inhibition (Supplementary Figure S1E ) in a dose-dependent manner. Together, these data indicate that miR-24 targets Jab1 by binding to its 3′UTR and 5′UTR, leading to Jab1 mRNA degradation and translational repression.
MiR-24 expression inversely correlates with Jab1 levels both in vitro and in vivo
To further confirm the correlation between miR-24 and Jab1, qRT-PCR and western blotting analysis were performed to measure the Jab1 mRNA and protein expression levels in a panel of cell lines, including the normal keratinocyte cell line HOK16B, non-cancerous human immortalized nasopharyngeal epithelial cell line NP460 and five NPC cell lines (CNE-1, CNE-2, CNE2R, HONE-1 and C666.1). As shown in Figures 4a and b, the expression levels of miR-24 and Jab1 were correlated negatively. The cells with the relatively low endogenous miR-24 expression level exhibited high levels of Jab1, and inversely. These data showed an in vitro inverse correlation between miR-24 and Jab1.
To confirm this inverse correlation in vivo, we tested the Jab1 level in NPC cells infected with LV expressing miR-24. Western blotting analysis confirmed that stable expression of miR-24 downregulated Jab1 levels compared with control ( Figure 4c ). We next evaluated the impact of miR-24 stable expression on xenograft tumor formation. Xenograft tumors overexpressing miR-24 showed a significant reduction in Jab1 levels compared with control-miR by immunohistochemical analysis (Figures 2 and 4d; P = 0.004), providing evidence of the inverse correlation between miR-24 and Jab1 in vivo. miR-24 targets Jab1/CSN5 in nasopharyngeal carcinoma S Wang et al Jab1 expression is induced by IR and silencing Jab1 replicates the effects of miR-24 under IR, whereas exogenous expression of Jab1 without its 3′UTR and 5′UTR can rescue the inhibition effect by miR-24 To explore whether Jab1 could mediate the function of miR-24 in NPC as a tumor suppressor and radiosensitizer, we detected both miR-24 and Jab1 expression after irradiation of NPC cells. MiR-24 was downregulated (over twofold) after irradiation in a dosedependent manner, as shown by qRT-PCR analysis (Figure 5a ), whereas Jab1 was upregulated (over twofold) accordingly at the protein level ( Figure 5b ). This finding suggests that the Jab1 increase under IR might be due to the inhibition of miR-24 postirradiation. To further identify the role of Jab1 in mediating miR-24 function under IR, NPC cells (CNE-1 and CNE-2) were infected with an LV expressing an small hairpin RNA (shRNA) targeting Jab1 (Supplementary Figure S2C ). After treatment with IR, loss of Jab1 increased NPC cell response to radiation in both CNE-1 and CNE-2 cells (Figures 5c and d, P o0.001), consistent with the function of miR-24 ( Figure 1b ). Additionally, cell apoptosis was further increased (around twofold) in Jab1-deleted cells (Figures 5e and f) and miR-24-overexpressing cells (Figure 1c ). Interestingly, our colony-formation assay data revealed that the inhibition effect of Jab1 by miR-24 (under IR or not) could be rescued significantly (0 Gy: 1.2-fold vs 2.2-fold; 2 Gy: 1.6-fold vs 3.7fold; Figure 5g , P o0.001) when overexpressed exogenous Jab1 without its 3′UTR and 5′UTR (Figure 5h ). Taken together, our present evidences showed that miR-24 exerts its effect on NPC tumorigenesis and radioresistance by targeting Jab1. Jab1 expression in NPC patients inversely correlated with miR-24, and both associated with NPC recurrence To reduce genetic variation between NPC patients, 50 samples from 25 NPC patients (paired primary and matched recurrent NPC tissues from the same patients) were collected and subjected to a novel microarray analysis, the high-throughput genomic qNPA (from HTG Molecular) for quantifying simultaneously miR and β-Actin was used as an internal control. Data were quantified using the ImageJ software. (g) Western blotting results of Jab1 protein level by transfecting with miR-24 inhibitors in a dose-dependent manner. β-Actin was used as an internal control. Data were quantified using the ImageJ software.
miR-24 targets Jab1/CSN5 in nasopharyngeal carcinoma S Wang et al mRNA levels from the same patient sample, to further validate the miR-24-Jab1 pathway in NPC. qNPA is a well-established approach for quantifying gene expression (including mRNAs and miRs). 31 Because of the scant biopsy material from NPC patients, qNPA is an optimal approach for measuring the miRs and gene expression levels on the same sample using formalin-fixed, paraffinembedded (FFPE) tissues.
Of importance, the expression level of miR-24 was found to be significantly lower in recurrent NPC tissues than in the paired primary tissues from the same patients (Figure 6a , P = 0.001), with a lower expression level observed in 84% (N = 21/25) of recurrent NPC tissues compared with matched primary tissues (Supplementary Figure S3A) . Also, the Jab1 mRNA expression level was found to be significantly higher in recurrent NPC tissues than in the paired primary tissues (Figure 6b , P = 0.006), with a higher level seen in 88% (N = 22/25) of recurrent NPC tissues compared with matched primary tissues (Supplementary Figure S3B , N = 22/25), thus revealing an inverse correlation between miR-24 and Jab1 in NPC patients. To further correlate the expression of miR-24 and Jab1 mRNA from the same samples, we utilized a heat map to show the association more clearly (Figure 6c) . The Spearman correlation test results indicated a strong inverse correlation between miR-24 and Jab1 mRNA levels in NPC patient samples (Figure 6c , R = − 0.521, P = 0.008). The detailed inverse correlation between miR-24 and Jab1 from NPC samples is also shown in Supplementary Figure S3C . All together, these data provide solid evidence that elevated Jab1 expression negatively correlated with reduced miR-24 expression.
In terms of the Jab1 mRNA degradation and translational inhibition by miR-24 from in vitro data, we next detected the Jab1 protein level in NPC primary and recurrent samples from 25 patients by immunohistochemical analysis (same patient set as that of qNPA patient set). Jab1 was expressed to a higher degree in both nucleus and cytoplasm in the recurrent NPC samples than in the primary NPC samples (Figures 6d-f ). This result is consistent with Jab1 mRNA expression levels, which were also inversely correlated with miR-24 expression in NPC patient samples, further confirming the translational repression of Jab1 by miR-24 in NPC patient samples.
To identify the crucial role of miR-24 and Jab1 in NPC recurrence, we performed Kaplan-Meier analyses of miR-24 and Jab1 expression, using the interval from initial treatment to NPC recurrence. MiR-24 was positively correlated with the interval from initial treatment to recurrence (Figure 6g , Supplementary Table S1 , P = 0.002). Although low Jab1 mRNA levels correlated positively with a longer interval to recurrence, the P-value was not significant (Supplementary Figure S3D , Supplementary Table S2 ). However, Jab1 protein expression in both nucleus (Supplementary Figure S3E , Supplementary Table S3 , P = 0.000) and cytoplasm (Figure 6h , Supplementary Table S4 , P = 0.000) correlated negatively with the interval. Herein we report for the first time that miR-24 downregulation or Jab1 upregulation at the protein level in NPC recurrent tissues is closely associated with a shorter interval from initial treatment to NPC recurrence, indicating the potential roles of miR-24 and Jab1 as prognostic markers for NPC recurrence. Together, our findings define a central role for miR-24 as a tumor-suppressive miR in NPC and suggest its use in novel strategies for treatment of this cancer. 
DISCUSSION
NPC radioresistance following radiotherapy is the major cause for NPC treatment failure. 5 Studies have reported that miR expression changes upon IR treatment in different cell types. Investigation of the use of miRs as drugs or drug targets against tumors is under way. 32, 33 A few molecular-targeting drugs have shown clinical activity against advanced NPC, 34 and the use of miR as a therapeutic strategy is a promising strategy. It has been reported that lentiviral vectors have been applied successfully to deliver miRs for gene therapy of NPC. Silencing the radioresistance manganese superoxide dismutase (SOD2) by miR-155 could reduce NPC resistance to IR, 35 and lenti-miR-26a inhibited the tumorigenicity of NPC cells in nude mice. 36 These studies indicate the potential application of miRs in increasing NPC sensitivity to radiotherapy and inhibiting NPC development.
Sufficient evidence shows that a subset of tumors, such as colorectal and gastric cancer, has reduced levels of miR-24, indicating its potential role as a tumor-suppressive miR, 37 which is consistent with our results in NPC model. MiR-24 overexpression could induce apoptosis in endothelial cells, 38 facilitating TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis via restored function of the canonical apoptosis pathway by targeting the 3′UTR of XIAP, leading to the activation of intracellular caspase-8. 13 In addition, miR-24 can also regulate cell cycle progression by inhibiting the cell cycle. 39 Another group previously documented that overexpression of miR-24 led to higher chromosomal breaks and sensitivity to IR, 40 supporting our findings in this NPC model. Certain miRs are decreased in response to IR, and overexpressing these miRs makes cells more sensitive to radiation, and vice versa. For example, let-7b is markedly downregulated following IR, and overexpression of let-7b increases radiosensitivity, whereas inhibiting let-7b reduces radiosensitivity. 41 Therefore, it is possible to develop miR-24 as an antitumor agent to enhance radiosensitivity and improve the efficacy of radiotherapy.
On the other hand, we observed a lower expression level of miR-24 in recurrent NPC samples compared with matched primary samples from the same patients. Low expression of miR-24 was associated with a short interval from initial treatment to NPC recurrence, indicating the possible use of miR-24 as a biomarker for NPC recurrence. A lower miR-24 expression level in recurrent NPC samples compared with primary samples indicates a greater chance of reoccurrence. Detecting circulating cell-free miRs released from secretion of cancer cells would avoid the need for tumor tissue biopsies. 42 Therefore, measurement of miR-24 expression in the patient's body fluids may be a feasible method to predict reoccurrence in patients with primary NPC.
Jab1 is an oncoprotein and prognostic marker for multiple cancers. It has an important role in cell proliferation, apoptosis and the regulation of genomic stability and DNA repair. Dysregulation of Jab1 contributes to oncogenesis by functionally inactivating key negative regulatory proteins such as p27, 43 leading to their degradation. Knockdown of Jab1 inhibits proliferation and induces apoptosis in hepatocellular carcinoma cells. 44 In NPC, high expression of Jab1 (Pan et al. 21 ) contributed to an advanced stage of NPC and a low overall survival rate. Systemic delivery of the modified CSN5 siRNA encapsulated in stable nucleic acid lipid particle remarkably inhibited hepatic tumor growth in an orthotopic xenograft model of human liver cancer, 44 indicating Jab1 to be a promising novel target for anticancer therapy.
Jab1 can also mediate the nuclear export and degradation of DNA damage and repair proteins. Double-strand breaks arising during meiotic recombination cannot be efficiently repaired in Jab1-mutant cells. 45 DNA-damaging agents are commonly used as important cancer therapies, triggering DNA repair and then rendering the cells resistant to therapy. NPC is one of the typical examples where Jab1 is involved in NPC radioresistance. 21 In this study, we demonstrated for the first time that miR-24 binds to both the 3′UTR and 5′UTR of Jab1, leading to Jab1 mRNA degradation and translational repression. Although it is common for miRs to target 3′UTR of its targets resulting in translational repression, 39 we reported here that both the 3′UTR and 5′UTR of Jab1 could be targeted by miR-24, and overexpression of Jab1 without both 3′UTR and 5′UTR could rescue the inhibition effect mediated by miR-24 with or without IR treatment. Translational inhibition is often a consequence of mRNA deadenylation and degradation. 46, 47 The effects of miRs targeting 5′UTR of mRNA are contradictory. Jopling et al. 48 first reported in 2005 that miR-122 could bind to the 5′UTR of its targets, leading to translational inhibition. However, in 2008, miR-10a was reported to bind ribosomal protein mRNAs at the 5′UTR downstream of the conserved 5′TOP motif, enhancing their translation. 49 This may be due to the fact that some miRs can induce translation of target mRNAs during cell cycle arrest.
Furthermore, observed miR-24 levels correlated inversely with Jab1 mRNA and protein levels in both NPC cells and NPC patients. MiR-24 expression was reduced while Jab1 was induced under IR treatment, and knockdown of Jab1 could largely imitate the function of miR-24. Additionally, a higher expression level of Jab1 was observed in recurrent NPC samples compared with the matched primary samples from the same patients, and Jab1 is associated with a short interval from initial treatment to NPC recurrence, representing a possible biomarker for NPC recurrence. All in all, we determined that Jab1 as an oncoprotein in NPC can be blocked by miR-24, presenting a novel approach for treating NPC and reversing NPC radioresistance. Other targets of miR-24, in addition to Jab1, are to be discovered to achieve its full activity. Our elucidation of the intricate network and roles of miR-24 in NPC development and therapy failure will allow for specific therapeutic approaches for NPC patients.
MATERIALS AND METHODS

Patient samples
Fifty FFPE human primary and matched recurrent NPC tissues were obtained from 25 NPC patients between 2001 and 2012 from First People's Hospital of Foshan (30 samples) and Shantou Central Hospital (20 samples), both affiliated with Sun Yat-Sen University. Patients with both primary and recurrent NPC after radiotherapy were chosen to participate in this study. Ethics approval was given by these two hospitals, and fully informed consent was obtained from all patients before sample collection. In this study, primary NPC indicates a patient with a diagnosis of NPC for the first time, prior to any therapy. Recurrent NPC indicates the same patient who has NPC reoccurrence in the local region after radiotherapy. The clinicopathological characteristics of the NPC patients are listed in Supplementary Table S5 .
Cell lines and cell culture
Cells of the normal keratinocyte cell line HOK16B has been described previously 21 and were cultured in keratinocyte-SFM basal medium containing 30 μg/ml bovine pituitary extract, 0.2 ng/ml epidermal growth factor, 5% fetal bovine serum (FBS) and 0.5% penicillin-streptomycin sulfate. Cells of the non-cancerous human immortalized nasopharyngeal epithelial cell line NP460 (a generous gift from Professor George Sai Wah Tsao, Department of Anatomy, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China) were cultured in keratinocyte-SFM basal medium combined with Epilife medium at a 1:1 ratio, supplemented with growth factors, 2% FBS and 0.5% penicillin-streptomycin sulfate. The human NPC cell lines CNE-1 (well differentiated), CNE-2 (poorly differentiated), HONE-1 (poorly differentiated) and C666.1 (undifferentiated) have been described previously. CNE-2R, a radioresistant cells, was established by exposing CNE-2 cells to an increasing doses of IR and has been described previously. 50 All the NPC cells were cultured in RPMI 1640 medium containing 10% FBS and 0.5% penicillin-streptomycin sulfate. NPC cells (CNE-2R) stably overexpressing miR-24 or not by transduction with LV expressing mir-LV-24-1 or mir-LV-control were maintained in medium containing puromycin at a concentration of 4 μg/ml. NPC cells miR-24 targets Jab1/CSN5 in nasopharyngeal carcinoma S Wang et al (CNE-1, CNE-2) with Jab1 knockdown or not by infection with a LV expressing a shRNA targeting sh-Jab1 or sh-Ctrl were maintained in medium containing puromycin at a concentration of 0.2 μg/ml puromycin. All cell lines were digested with 0.25% trypsin except for NP460 and C666.1, which were digested with 0.05% trypsin. Cells were stained with trypan blue and counted using a Countess automated cell counter (Invitrogen, Carlsbad, CA, USA).
Reagents and chemicals
All cell culture media were purchased from Mediatech (Manassas, VA, USA) and Gibco (Grand Island, NY, USA). Phosphate-buffered saline (PBS) and chemiluminescent western blotting substrate were from ThermoFisher Scientific (Grand Island, NY, USA). Trypsin, hematoxylin, β-actin antibody (Cat. no. A5441) and the primers for reporter pMIR-Luc-Jab1 and mutation were from Sigma-Aldrich ( 
MiR-24 mimic and miR-24 inhibitor transfection studies
Exponentially growing NPC cells were plated onto six-well plates using medium without antibiotics 24 h before transfection. mirVana miR-24 mimics, miRNA inhibitor or miR control (Ambion) was transfected using Lipofectamine 2000 as a carrier at a 1:1 ratio to overexpress the mature miR-24 level, to inhibit the level or as a control. Opti-MEM medium (Gibco) was replaced with regular culture medium without antibiotics after transfection for 6 h. Cells were harvested to extract protein and RNA.
Quantitative real-time PCR
qRT-PCR was used to detect miR-24 and Jab1 mRNA levels. Cells were harvested using Trizol (Ambion). For detection of mature miR-24, reverse transcription was performed to convert RNAs to cDNAs using a TaqMan miRNA Reverse-Transcription Kit. For Jab1 detection, reverse transcription was performed using the ImProm-II reverse transcription system. PCR reaction mixtures containing TaqMan universal master mix II (miR-24) or SYBR Green PCR master mix (Jab1) and TaqMan miRNA or gene expression assays (Applied Biosystems) were used according to the manufacturers' protocols (gradient S, Mastercycler, Eppendorf, Hamburg, Germany). Cycling variables were as follows: 50°C for 2 min and 95°C for 10 min followed by 40 cycles at 95°C (15 s) and annealing/extension at 60°C (1 min). Data were analyzed with 2 − ΔΔCt for relative changes in miR or 
Colony-formation assay
The colony-formation assay was used to analyze cell growth after treatment with miR-24 mimics or IR. After approximately 10 days, cell colonies were washed with PBS, fixed with methanol, stained by 0.1% crystal violet and scored by counting the number of colonies with an inverted microscope, using the standard definition that a colony consists of ⩾ 50 cells. The inhibition ratios (%) of colony formation were calculated as the ratio of the indicated treatment group to the control group as follows: % inhibition ratio = 100% × Nt/Nc, where Nt is the number of the treatment group colonies and Nc is the number of control group colonies.
Irradiation studies
In vitro irradiation was performed using a Gammacell 1000 irradiator (Nordion, Ottawa, ON, Canada) with iodine-131 at MD Anderson Cancer Center. Cells were suspended in cell medium before irradiation at a rate of 283 rads/min. 
Lentivirus infection, constitutive expression and miR stable expression
CNE-2 R cells were seeded (1.5 × 10 4 per well) onto a 12-well plate 1 day before transduction with hsa-mir-LV-24-1 or mir-LV-control. Medium was replaced by new medium containing 6 μg/ml Polybrene, and 100 μl of mir-LV-24-1 or mir-LV-control was added, followed by centrifugation at 1000 g for 40 min at room temperature. When cell confluence was 450%, transduced cells were selected by puromycin at a concentration of 4 μg/ml. Transduction efficiency was measured under a microscope, and a single colony was chosen to determine the differential transduction efficiency of the stable cells overexpressing miR-24 or not.
Mouse model
All experimental procedures using mice were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of the University of Texas MD Anderson Cancer Center. For the orthotopic xenograft tumor model, both flanks of 4-6-week-old male BALB/c athymic nu/ nu mice were subcutaneously injected with 50 μl of 1.0×10 6 NPC CNE-2R cells stably overexpressing miR-24 or miR-Control (in PBS) combined with 50 μl of Matrigel. When the tumor mass became palpable (at day 10 after injection), mice were randomly divided into a control group and an IR-treated group (five mice per group). The investigator was blinded to the group allocation during experiment. Mice in the IR-treated group were irradiated with a dose of 5 Gy and re-irradiated every 2 other day. Experiments were repeated twice. Tumors were measured every 2 days with digital calipers, and the tumor volume (in mm 3 ) was calculated using the formula: Volume = (L × W 2 )/2. Mice were killed on day 22 after injection, when some of the tumors reached the size limit set by the Institutional Animal Care and Use Committee. Mice were killed by CO 2 asphyxiation, and tumors were weighed after careful resection (two mice in the IR-treated group died 1 day before CO 2 asphyxiation).
Western blotting analysis
Western blotting analysis was performed as described previously. 21 Cell lysates were immunoblotted with purified mouse anti-human Jab1 antibody, and β-actin antibody was used as the internal positive control. Finally, the signals were developed with chemiluminescent western blotting substrate (ThermoFisher Scientific), and ImageJ64 software (NIH, Bethesda, MD, USA) was used to quantify signal intensity.
Immunohistochemical analysis
Jab1 expression at the protein level was detected immunohistochemically on 50 paraffin-embedded NPC tissues from 25 patients. Briefly, deparaffinized sections were treated with 10 mM sodium citrate buffer (pH 6.0) for heat-induced retrieval of the antigen and then immersed in 3% hydrogen peroxide solution to inhibit endogenous peroxidase activity, followed by incubation of the sections in 5% bovine serum albumin to block nonspecific binding. The sections were then incubated with primary antibodies against Jab1 (1:150) at 4°C overnight and then incubated with biotinylated secondary antibody followed by the Liquid DAB Substrate Chromogen System according to the manufacturer's instructions. Jab1 expression level was evaluated by counting at least 500 tumor cells in at least five representative high-power fields. The Jab1 staining in the nucleus and cytoplasm of the tumor cells were scored separately and scores combined for each case as described previously. 51 Computational analysis of miR-24 binding to Jab1
RNAhybrid can be used in a very simple version to find binding sites in a gene of interest that is posited to be regulated in the miRNA pathway. We therefore used RNAhybrid (http://bibiserv.techfak.uni-bielefeld.de/rnahy brid/submission.html; offered by BiBiServ, Bielefeld University Bioinformatics Server), which is unique in offering a flexible online prediction, to predict the binding sites of miR-24 to Jab1 with the secondary structure and MFEs. MFEs result from the optimization of duplexes between a miRNA and a putative target sequence. 29, 30 Vector construction and mutagenesis of predicted binding sites of Jab1
To generate a luciferase reporter for evaluating miR activity, we amplified two fragments of Jab1 mRNA (3′UTR and 5′UTR) by PCR from genomic DNA isolated from NPC cell CNE-2. Inserts were retrieved with HindIII and SpeI and cloned into the same sites of pMIR-REPORT Lucirefase vector (Applied Biosystems) downstream of the firefly open reading frame for the Jab1 3′UTR and 5′UTR and in the BamH1 site (pMIR-REPORT) upstream of the luciferase open reading frame for the Jab1 5′UTR Upstream. The primers for PCR amplification were as follows: 3′UTR: Sense: 5′-CGCACTAGTACAGTCTCTGAGAAGTACTTTACCTG-3′; Anti-sense: 5′-GGTAAGCTTTTCATTTTAAAGAGCTTTATTACAGG-3′. 5′UTR: Sense: 5′-CGCACTAGTGACTATACCACTCCCATACCCT-3′; Anti-sense: 5′-AATAAGCTTCGCCGAGGAAGCGGAGAA-3′. 5′UTR-Upstream: Sense: 5′-CGGGATCCGACTATACCACTCCCATACCCTA-3′; Anti-sense: 5′-TCCGTGGATCCCGCCGAGGAAGCGGAGAAGTTG-3′. The QuikChange Multi Site-Directed Mutagenesis Kit was used to generate the mutation in the predicted binding sites. Four nucleotides (AGCT) in the 3′UTR of the Jab1 gene or GGTC in the 5′UTR of Jab1 were deleted by PCR from the wild-type Jab1 gene. Both wild-type and mutant inserts were confirmed by sequencing (DeWalch Technologies, Houston, TX, USA). The primers for mutation were as follows:
3′UTR mutant: AGCT deletion: Forward: 5′-CAAGGATTTATAATTATAGGACATTATTGAAATTTTAC-3′; Reverse: 5′-GTAAAATTTCAATAATGTCCTATAATTATAAATCCTGTG-3′. 5′UTR mutant: GGTC deletion: Forward: 5′-AAACAAGGGCACCACGCCTCTTCCGGGTGTGGGCCTT-3′; Reverse: 5′-AAAGGCCCACACCCGGAAGAGGCGTGGTGCCCTTGTTT-3′.
Dual luciferase reporter assay
Luciferase plasmids (pMIR) containing 5′-UTR or 3′-UTR of Jab1 were transiently transfected with miR-24 mimics into CNE-2 cells. Cells were seeded onto 24-well plates and co-transfected 24 h later with pMIR-5′-UTR or 3′-UTR, 30 nmol/l miR-24 mimics or miR control and a pRL plasmid control using PLUS reagent (Invitrogen) following the manufacturer's protocol. After 48 h, cells were washed and resuspended in the lysis buffer, and the luciferase activity was assayed with a luminometer using the Dual-Light system (Promega). All experiments were performed in triplicate, and the results are presented as the means of these separate experiments.
Establishment of shRNA stable cells
To knockdown Jab1 in NPC cells, CNE1 and CNE2 cells were stably transfected with Jab1 shRNA (sh-Jab1) or control shRNA (sh-Cont) as described previously. 23 Briefly, Jab1 shRNA oligonucleotides were cloned into a retrovirus pSIREN-RetroQ system (Clontech, Mountain View, CA, USA). The packaging cell line 293T was co-transfected with Jab1 miR-24 targets Jab1/CSN5 in nasopharyngeal carcinoma S Wang et al shRNA-vector DNA along with the vectors pCGP and pVSVG using the Lipofectamine PLUS reagent. Stable clones were selected following treatment with puromycin at 0.8 μg/ml for 2 weeks. Positive clones were further confirmed by immunoblot analysis and maintained in 0.2 μg/ml puromycin.
Quantitative nuclease-protection assay
A total of 50 FFPE NPC samples (25 primary, 25 recurrent) were analyzed for miR and gene expression profiling (HTG Molecular qNPA service, Tucson, AZ, USA). Briefly, section areas were measured and scraped from the slides. Tissues were then lysed in HTG lysis buffer to a concentration of approximately 0.1 cm 2 per well. Nuclease protection probes were added first to hybridize the samples, and S1 nuclease was then added to degrade the non-hybridized single-strand molecules. Samples were then transferred to the reader plate, followed by adding programming linkers for capturing specific nuclease protection probes (HTG Molecular). Detection linkers and biotinylated detection probes were then added one after the other to bind to the probes and detect the linkers. Avidin-horseradish peroxidase as substrate was finally added for the chemiluminescence detection. All samples were analyzed in triplicate, and Universal Human Reference RNA was analyzed in triplicate (100 ng/well) on each plate as a qNPA array plate run control.
Statistical data analysis
Statistical analysis was performed using the SPSS statistical software (SPSS, Chicago, IL, USA). Statistical evaluation for data analysis used Student's t-test when there were only two groups (two sided). The paired t-test was used to calculate the P-value of miR-24 and Jab1 expression between primary and recurrent NPC tissues (two sided). The Spearman correlation test was used to calculate the correlation coefficient (r) and P-value for the correlation between miR-24 expression and Jab1 expression. Kaplan-Meier curves were drawn to show the association of miR-24 or Jab1 expression and the interval from initial treatment to recurrence, with P-values from log-rank analysis. All data are reported as means ± s.d. Differences between groups were considered significant statistically when P ⩽ 0.05.
